Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

NCT00807027 is registered in ClinicalTrials.gov with GC Cell Corporation as lead sponsor.

NCT NCT00807027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00807027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
Lead sponsor
GC Cell Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 5, 2008
Completion date
October 31, 2012
Enrollment
180 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma